

# Out- Licensing

[cphi.evapharma.com](http://cphi.evapharma.com)

2021





# About Us

At EVA Pharma, we pride ourselves on our innovation and our expertise, built on a heritage spanning over a hundred years.

We offer licensing of a broad portfolio of generic products in different dosage forms, including solids, semi-solids, sterile products, patches, and respiratory products, among others.

We provide flexible business models (from pure CMO to tech transfer, co-developments or standard licensing), high-service regulatory

support, door-to-door logistics management, and investment in future pipeline projects.

Due to the local patent situation, EVA Pharma can develop and market products at an early stage, before they are produced for other markets, allowing us to generate knowledge about production before commercial launch, including on early economies of scale and long-term price competitiveness.





# Building Successful Partner- ships

EVA Pharma has a record of successful partnerships in a variety of areas.

We have been recognized as the partner of choice by several multinational companies in Europe through out-licensing the company's unique eCTD dossiers, which are now registered in more than ten EU countries.

In 2019, we partnered with Gilead Sciences to become a licensed distributor for their HIV, HBV and HCV products in Africa, and in 2020 we acquired the license to manufacture and distribute Gilead's COVID-19 antiviral remdesivir, going on to export it to dozens of countries.

In addition, in 2020, EVA Group signed a strategic partnership agreement with Eli Lilly and Company to import, distribute, market and sell Lilly's portfolio of brands in Egypt.








# Partner With Us

We are particularly interested in building on our existing out-licensing partnerships in the US, the EU, and the UK.



**EVA PHARMA**  
SECURING YOUR HEALTH

**Get in touch to discuss how we can  
help you deliver your project.**

[cphi.evapharma.com](http://cphi.evapharma.com)